Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 12/2016

01-12-2016 | Brief Report

The −2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients

Authors: Emilia Saint Martin, Emilce E. Schneeberger, Federico M. Aranda, Silvia Wingeyer Peres, María del Carmen Valerio, Maria de los Angeles Correa, Fernando Dal Pra, Liliana Martinez, Graciela Remondino, Gabriela de Larrañaga, Gustavo Citera

Published in: Clinical Rheumatology | Issue 12/2016

Login to get access

Abstract

The aim of this study was to analyze the influence of nucleotide transition (G/A) in position −2518 of the MCP-1 gene related to the susceptibility of developing RA. Two hundred twenty-three consecutive RA patients according to 2010 ACR/EULAR criteria were included; 120 healthy subjects were used as controls. MCP-1 −2518 A/G polymorphism (AG + GG) was present in 162 (72.6 %) RA patients and in 63 (52.5 %) healthy subjects [OR 2.44 (IC95% 1.53–3.88, p = 0.0002)]; associations for heterozygotes and homozygotes were OR 1.92 (IC95% 1.19–3.15, p = 0.001) and OR 5.19 (IC95% 2.34–11.51, p = 0.001), respectively. In Argentine patients, MCP-1 gene polymorphism confers susceptibility for developing RA.
Literature
1.
2.
Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein 1 (MCP-1): an overview. J Interf Cytokine Res 29(6):313–326CrossRef
3.
Villiger PM, Terkeltaub R, Lotz M (1992) Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. J Clin Invest 90(2):488–496CrossRefPubMedPubMedCentral
4.
Hayashida K, Nanki T, Girschik H, Yavuz S, Ochi T, Lipsky PE (2001) Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 3(2):118–126CrossRefPubMedPubMedCentral
5.
El-Gabalawy HS, Robinson DB, Smolik I, Hart D, Elias B, Wong K, et al. (2012) Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum 64(6):1720–1729CrossRefPubMed
6.
Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G (2007) Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis 66(1):121–123CrossRefPubMed
7.
Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259(2):344–348CrossRefPubMed
8.
González-Escribano MF, Torres B, Aguilar F, Rodríguez R, García A, Valenzuela A, et al. (2003) MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis. Hum Immunol 64(7):741–744CrossRefPubMed
9.
Lee YH, Kim HJ, Rho YH, Choi SJ, Ji JD, Song GG (2003) Functional polymorphisms in matrix metalloproteinase-1 and monocyte chemoattractant protein-1 and rheumatoid arthritis. Scand J Rheumatol 32(4):235–239PubMed
10.
Hwang SY, Cho ML, Park B, Kim JY, Kim JH, Min DJ, et al. (2002) Allelic frequency of the MCP-1 promoter −2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult onset Still’s disease. Eur J Immunogenet 29(5):413–416CrossRefPubMed
11.
Pavkova Goldbergova M, Lipkova J, Pavek N, Gatterova J, Vasku A, Soucek M, et al. (2012) RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis. Mol Immunol 52(3–4):273–278CrossRefPubMed
12.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRefPubMed
13.
14.
Corach D, Lao O, Bobillo C, van Der Gaag K, Zuniga S, Vermeulen M, et al. (2010) Inferring continental ancestry of argentineans from autosomal, Y-chromosomal and mitochondrial DNA. Ann Hum Genet 74(1):65–76CrossRefPubMed
15.
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48CrossRefPubMed
16.
Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, Sanchez MM, Goni MA, et al. (2004) Validation and crosscultural adaptation of an Argentine Spanish version of the health assessment questionnaire disability index. J Clin Rheumatol 10(3):110–115CrossRefPubMed
17.
van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27(1):261–263PubMed
18.
Muñoz SA, Aranda F, Allievi A, Orden AO, Peres Wingeyer S, Trobo R, et al. (2014) 4G/5G plasminogen activator inhibitor-1 and −308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis. Clin Exp Med 14(1):83–89CrossRefPubMed
19.
Ozyurek AR, Gurses D, Ulger Z, Levent E, Bakiler AR, Berdeli A (2007) Allelic frecuency of the MCP-1 promoter −2518 polymorphism in the turkish population and in turkish patients with juvenile rheumatoid arthritis. Clin Rheumatol 26(4):546–550CrossRefPubMed
20.
Lee YH, Bae SC (2016) Monocyte chemoattractant protein-1 promoter −2518 polymorphism and susceptibility to vasculitis, rheumatoid arthritis, and multiple sclerosis: a meta-analysis. Cell Mol Bioj (Noisy-le-grand) 62(3):65–71
21.
Chen S, Deng S, Hu C, Li J, Wen X, Wu Z, et al. (2016) Association of MCP-1-2518 A/G poymorphism with susceptibility to autoimmune diseases: a meta analysis. Clin Rheumatol 35(5):1169–1179CrossRefPubMed
Metadata
Title
The −2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients
Authors
Emilia Saint Martin
Emilce E. Schneeberger
Federico M. Aranda
Silvia Wingeyer Peres
María del Carmen Valerio
Maria de los Angeles Correa
Fernando Dal Pra
Liliana Martinez
Graciela Remondino
Gabriela de Larrañaga
Gustavo Citera
Publication date
01-12-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3380-0

Other articles of this Issue 12/2016

Clinical Rheumatology 12/2016 Go to the issue

Original Article

Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission

Review Article

Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions

Original Article

Disease-specific pain and function predict future pain impact in hip and knee osteoarthritis

Original Article

How is the ultrasound in rheumatology used, implemented, and applied in Latin American centers? Results from a multicenter study

Original Article

Hypogonadism and the risk of rheumatic autoimmune disease

Original Article

A discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits